These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37862822)

  • 1. Cost-utility analysis of teduglutide compared to standard care in weaning parenteral nutrition support in children with short bowel syndrome.
    Gattini D; Belza C; Kraus R; Avitzur Y; Ungar WJ; Wales PW
    Clin Nutr; 2023 Dec; 42(12):2363-2371. PubMed ID: 37862822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of teduglutide in adult patients with short bowel syndrome - a European socioeconomic perspective.
    Walter E; Dawoud C; Hütterer E; Stift A; Harpain F
    Am J Clin Nutr; 2024 May; 119(5):1187-1199. PubMed ID: 38431119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of teduglutide in adult patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
    Raghu VK; Binion DG; Smith KJ
    Am J Clin Nutr; 2020 Jan; 111(1):141-148. PubMed ID: 31665212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study.
    Germán-Díaz M; Alcolea A; Cabello V; Blasco-Alonso J; Rodríguez A; Galera R; García-Romero R; Romero C; González-Sacristán R; Redecillas-Ferreiro S; Moreno-Villares JM; Ramos-Boluda E
    Eur J Pediatr; 2024 Aug; 183(8):3173-3182. PubMed ID: 38664251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.
    Lam K; Schwartz L; Batisti J; Iyer KR
    JPEN J Parenter Enteral Nutr; 2018 Jan; 42(1):225-230. PubMed ID: 29505151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of teduglutide in pediatric patients with short bowel syndrome: Markov modeling using traditional cost-effectiveness criteria.
    Raghu VK; Rudolph JA; Smith KJ
    Am J Clin Nutr; 2021 Jan; 113(1):172-178. PubMed ID: 33021637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.
    Joly F; Seguy D; Nuzzo A; Chambrier C; Beau P; Poullenot F; Thibault R; Armengol Debeir L; Layec S; Boehm V; Lallemand J; Quilliot D; Schneider SM
    Clin Nutr; 2020 Sep; 39(9):2856-2862. PubMed ID: 31932048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
    Jeppesen PB; Gabe SM; Seidner DL; Lee HM; Olivier C
    Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.
    Wales PW; Hill S; Robinson I; Raphael BP; Matthews C; Cohran V; Carter B; Venick R; Kocoshis S
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):290-300. PubMed ID: 38873891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Variable Response to Teduglutide in Pediatric Short Bowel Syndrome: A Single Country Real-Life Experience.
    Guz-Mark A; Hino B; Berkowitz D; Hartman C; Millman PN; Orlanski-Meyer E; Shaoul R; Spector-Cohen I; Weiss B; Zangen T; Shamir R
    J Pediatr Gastroenterol Nutr; 2022 Sep; 75(3):293-298. PubMed ID: 35730756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB; Pertkiewicz M; Forbes A; Pironi L; Gabe SM; Joly F; Messing B; Loth S; Youssef NN; Heinze H; Berghöfer P
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.
    Carter BA; Cohran VC; Cole CR; Corkins MR; Dimmitt RA; Duggan C; Hill S; Horslen S; Lim JD; Mercer DF; Merritt RJ; Nichol PF; Sigurdsson L; Teitelbaum DH; Thompson J; Vanderpool C; Vaughan JF; Li B; Youssef NN; Venick RS; Kocoshis SA
    J Pediatr; 2017 Feb; 181():102-111.e5. PubMed ID: 27855998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of Teduglutide in Pediatric Patients With Intestinal Failure due to Short Bowel Syndrome: A 24-Week, Phase III Study.
    Kocoshis SA; Merritt RJ; Hill S; Protheroe S; Carter BA; Horslen S; Hu S; Kaufman SS; Mercer DF; Pakarinen MP; Venick RS; Wales PW; Grimm AA
    JPEN J Parenter Enteral Nutr; 2020 May; 44(4):621-631. PubMed ID: 31495952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with teduglutide treatment for short bowel syndrome in clinical practice.
    Pevny S; Maasberg S; Rieger A; Karber M; Blüthner E; Knappe-Drzikova B; Thurmann D; Büttner J; Weylandt KH; Wiedenmann B; Müller VA; Bläker H; Pascher A; Pape UF
    Clin Nutr; 2019 Aug; 38(4):1745-1755. PubMed ID: 30145039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of teduglutide in adults with short bowel syndrome-associated intestinal failure.
    Pironi L; Allard JP; Joly F; Geransar P; Genestin E; Pape UF
    Nutr Clin Pract; 2024 Feb; 39(1):141-153. PubMed ID: 37294295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Therapy With Teduglutide in Parenteral Support-Dependent Patients With Short Bowel Syndrome: A Case Series.
    Ukleja A; To C; Alvarez A; Lara LF
    JPEN J Parenter Enteral Nutr; 2018 May; 42(4):821-825. PubMed ID: 29603279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Parenteral Nutrition Requirements and BMI in Patients with Parenteral Nutrition-Dependent Short Bowel Syndrome after Stopping Teduglutide-9 Years of Follow-Up.
    Zaczek Z; Jurczak-Kobus P; Panczyk M; Braszczyńska-Sochacka J; Majewska K; Kunecki M; Dąbrowska K; Sobocki J
    Nutrients; 2022 Apr; 14(8):. PubMed ID: 35458196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
    Jeppesen PB; Gilroy R; Pertkiewicz M; Allard JP; Messing B; O'Keefe SJ
    Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teduglutide-Stimulated Intestinal Adaptation Is Complemented and Synergistically Enhanced by Partial Enteral Nutrition in a Neonatal Piglet Model of Short Bowel Syndrome.
    Naberhuis JK; Deutsch AS; Tappenden KA
    JPEN J Parenter Enteral Nutr; 2017 Jul; 41(5):853-865. PubMed ID: 26304601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Teduglutide in Infants and Children With Short Bowel Syndrome Dependent on Parenteral Support.
    Chiba M; Masumoto K; Kaji T; Matsuura T; Morii M; Fagbemi A; Hill S; Pakarinen MP; Protheroe S; Urs A; Chen ST; Sakui S; Udagawa E; Wada M
    J Pediatr Gastroenterol Nutr; 2023 Sep; 77(3):339-346. PubMed ID: 37364133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.